

FOR IMMEDIATE RELEASE

Natrix Separations introduces new leadership team

New CEO and Business Development VP to spearhead new commercialization effort for downstream processing technology

Burlington, Ontario, October 28, 2011 — Natrix Separations, Inc. announced today new members of its leadership team, including John A. Chickosky as President & Chief Executive Officer and Molly S. McGlaughlin as Vice President of Business Development. Chickosky has been a member of the Natrix Board of Directors since mid-2010, and will continue to hold a board seat. McGlaughlin joined Natrix in June 2011.

C. Howie Honeyman, Ph.D. will continue as Senior Vice President, Research, Product Development & Applications and Robert Beveridge will remain as Chief Financial Officer.

The management team announcements coincide with a new round of investment from the existing slate of investors and a focused product development effort that is being conducted in close collaboration with biopharmaceutical industry leaders. The company is currently exploring additional collaboration partnerships to support this strategy.

Natrix Board Chairman Jim Iuliano commented, “John has been instrumental in assessing our technology and shaping our business strategy as a member of the board, and we are thrilled to have him leading the company during this exciting new phase of its development. He is widely respected among biopharm industry leaders and has demonstrated a deft hand in commercializing new technologies in this space.”

Chickosky added, “Natrix’s patented advective high-capacity chromatography technology has been well-received by the industry, and we are confident that it will deliver a step-change improvement in the way downstream processing is handled. We now have the right team and a focused plan to swiftly deliver the promise of Natrix’s core technology to customers who need it to meet the challenges of a rapidly changing bioproduction environment.”

Most recently, Chickosky was Chief Commercial Officer and President of the BioSystems Division of Xcellerex, Inc., where he led the development and execution of the company’s commercial strategy. He brings more than 20 years of senior management experience with life science technology companies, including senior positions at Kendro Laboratory Products (now part of ThermoFisher), CARR Separations, and Sepracor, Inc. John holds a Bachelor of Science

degree in Electrical Engineering and Computer Science from Santa Clara University and an MBA from St. Mary's College (California).

As Vice President of Business Development, Molly McGlaughlin is responsible for all commercial development and marketing for the company. Molly brings to Natrx more than 20 years of senior level biotechnology business development and marketing experience, most recently at Cytovance Biologics where she was Vice President of Sales and Business Development. Previously, she held commercial positions with leading life sciences companies including Avecia Biotechnology, Patheon and Tyco Healthcare. Molly is also a long-time member of the U.S. Army Reserves, where she is currently a Battalion Commander. She holds a B.S. in Biology from Norwich University, an M.Ed. from the University of Massachusetts, Boston, and is a Doctoral candidate in the school of Business and Technology at Capella University concentrating on M&A in the Biotechnology sector.

ABOUT NATRX SEPARATIONS

Natrix Separations is commercializing a new downstream bioprocessing technology based on its patented advective chromatography platform. Natrix technology combines the superior binding capacity of conventional resin-based column chromatography with the high throughput of membrane chromatography. This performance enables a new level of flexibility in downstream processing, eliminating the reliance on fixed, capital-intensive glass or stainless chromatography columns while also reducing buffer and other consumables costs by as much as 80%. Natrix technology is packaged in a single-use format, eliminating the cleaning, sanitization, storage, and validation burdens of conventional approaches. This format speeds facility turnaround and makes complete single-use biomanufacturing operation feasible and practical.

Natrix is currently exploring collaboration programs with leading biopharmaceutical organizations to advance the commercialization of its technology. For more information, please visit: www.natrixseparations.com.

CONTACT: Molly McGlaughlin
Natrix Separations
617-548-7927
mcgloughlin@natrixseparations.com